摘要
NSCLC患者易发生脑转移,治疗方法多样。酪氨酸激酶抑制剂（TKI）的广泛使用使得携带表皮生长因子受体（EGFR）基因突变的患者的生存得到显著延长。本文总结近年来有关TKI与NSCLC脑转移治疗的相关文献,探讨TKI与放疗联合的治疗模式。
Brain metastases （BM） are a frequent complication of non-small cell lung cancer （NSCLC） , with various treatment strategies. The widespread use of tyrosine kinase inhibitor （TKI） has significantly prolonged the survival of NSCLC patients with epidermal growth factor receptor mutations. This article reviews recent progress in TKI therapy for BM in NSCLC patients and discusses a combination of TKI and radiotherapy.
作者
孔月
宋正波
陈明
Kong Yue Song Zhenbo Chen Ming(Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou 310022, China Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2017年第10期1218-1221,共4页
Chinese Journal of Radiation Oncology
关键词
肺肿瘤
脑转移
酪氨酸激酶抑制剂
放射疗法
Lung neoplasms
Brain metastases
Tyrosine kinase inhibitor
Radiotherapy
